Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
28/06/2024 | 00:46 | Business Wire | Lawyers for Johnson & Johnson’s Ovarian Cancer Victims React to SCOTUS Decision in Purdue | NYSE:JNJ | Johnson and Johnson |
21/06/2024 | 13:30 | Business Wire | Johnson & Johnson Completes Acquisition of Proteologix, Inc. | NYSE:JNJ | Johnson and Johnson |
20/06/2024 | 22:30 | PR Newswire (US) | Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of moderately to severely active Crohn's disease | NYSE:JNJ | Johnson and Johnson |
20/06/2024 | 19:07 | Business Wire | More than 60 Law Firms Oppose J&J Prepack Bankruptcy Scheme | NYSE:JNJ | Johnson and Johnson |
20/06/2024 | 14:00 | PR Newswire (US) | TREMFYA® (guselkumab) studies underscore its potential to be the only IL-23 inhibitor to offer both subcutaneous and intravenous induction | NYSE:JNJ | Johnson and Johnson |
20/06/2024 | 12:55 | IH Market News | Trump Media Resells Stocks and Warrants; KB Home Exceeds Q2 Expectations, and More News | NYSE:JNJ | Johnson and Johnson |
17/06/2024 | 23:55 | Business Wire | Beasley Allen and Levin Papantonio: Leading Law Firms Seek Protection for Future Victims of Johnson & Johnson Talc Products | NYSE:JNJ | Johnson and Johnson |
17/06/2024 | 14:00 | PR Newswire (US) | Subcutaneous amivantamab Biologics License Application submitted to U.S. FDA for patients with EGFR-mutated non-small cell lung cancer | NYSE:JNJ | Johnson and Johnson |
15/06/2024 | 09:30 | PR Newswire (US) | Late-breaking results show nipocalimab significantly improves Sjögren's disease activity in a Phase 2 study | NYSE:JNJ | Johnson and Johnson |
14/06/2024 | 14:00 | PR Newswire (US) | TALVEY® (talquetamab-tgvs) demonstrates highly durable, longer-term responses in patients with relapsed or refractory multiple myeloma | NYSE:JNJ | Johnson and Johnson |
12/06/2024 | 20:26 | Business Wire | Talc Plaintiffs File Motion for Temporary Restraining Order to Limit Johnson & Johnson’s Use of Bankruptcy Strategy | NYSE:JNJ | Johnson and Johnson |
12/06/2024 | 13:19 | IH Market News | Paramount Ends Skydance Talks, Oracle Shares Surge 8.7% on New Partnerships, and More News | NYSE:JNJ | Johnson and Johnson |
06/06/2024 | 23:07 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NYSE:JNJ | Johnson and Johnson |
05/06/2024 | 13:41 | IH Market News | Apollo Buys 49% of Intel’s Irish Plant for $11bn, BlackRock and Citadel to Create Texas Exchange, and More News | NYSE:JNJ | Johnson and Johnson |
04/06/2024 | 22:30 | Business Wire | Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results | NYSE:JNJ | Johnson and Johnson |
31/05/2024 | 14:45 | Business Wire | Johnson & Johnson Completes Acquisition of Shockwave Medical | NYSE:JNJ | Johnson and Johnson |
29/05/2024 | 23:48 | PR Newswire (US) | Sarepta Therapeutics Set to Join S&P MidCap 400 | NYSE:JNJ | Johnson and Johnson |
28/05/2024 | 22:10 | Edgar (US Regulatory) | Form SD - Specialized disclosure report | NYSE:JNJ | Johnson and Johnson |
28/05/2024 | 13:35 | GlobeNewswire Inc. | Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for the Treatment of Atopic Dermatitis | NYSE:JNJ | Johnson and Johnson |
28/05/2024 | 13:30 | Business Wire | Johnson & Johnson to Obtain Rights to a Clinical-Stage Bispecific Antibody to Address Distinct Patient Needs in Atopic Dermatitis | NYSE:JNJ | Johnson and Johnson |
22/05/2024 | 18:05 | Business Wire | Proposed Class Action Filed by Six Law Firms Alleging Series of Fraudulent Transfers by Johnson & Johnson in Talc Litigation | NYSE:JNJ | Johnson and Johnson |
21/05/2024 | 16:43 | Edgar (US Regulatory) | Form CERT - Certification by an exchange approving securities for listing | NYSE:JNJ | Johnson and Johnson |
20/05/2024 | 23:17 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NYSE:JNJ | Johnson and Johnson |
20/05/2024 | 22:34 | Edgar (US Regulatory) | Form 8-A12B - Registration of securities [Section 12(b)] | NYSE:JNJ | Johnson and Johnson |
20/05/2024 | 22:01 | Edgar (US Regulatory) | Form 8-K - Current report | NYSE:JNJ | Johnson and Johnson |
20/05/2024 | 15:31 | Edgar (US Regulatory) | Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities | NYSE:JNJ | Johnson and Johnson |
17/05/2024 | 13:36 | IH Market News | OpenAI’s Reddit Partnership Boosts Shares by 14%, Microsoft Embraces AMD Chips for AI, and More News | NYSE:JNJ | Johnson and Johnson |
16/05/2024 | 22:16 | Edgar (US Regulatory) | Form 424B2 - Prospectus [Rule 424(b)(2)] | NYSE:JNJ | Johnson and Johnson |
16/05/2024 | 13:30 | Business Wire | Johnson & Johnson to Acquire Proteologix, Inc. to Lead in Atopic Dermatitis Treatment | NYSE:JNJ | Johnson and Johnson |
14/05/2024 | 23:01 | Edgar (US Regulatory) | Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses | NYSE:JNJ | Johnson and Johnson |